MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)

Inclusion Criteria: * Male or female patients must have r/r CD19-expressing ALL or NHL/CLL * CD19 expression must be detected on the malignant cells by flow cytometry (leukemia, malignant effusion in NHL) or immunohistochemistry (NHL); * Age ≥ 1 year (if deemed fit by treating investigator); * Absolute CD3+ T cell count ≥100/μl; * ECOG performance score of 0-2 if \>16 years old, or Lansky performance score of \>50 if ≤16 years old at screening; * No active Hepatitis B, Hepatitis C, HIV1/2; * No childbearing potential or negative pregnancy test at screening and before chemotherapy in women with childbearing potential; * Signed and dated informed consent/assent by patients * and meet the following disease-specific criteria: ALL: * patients with \>5% blasts in BM (M2 or M3) after at least one standard chemotherapy and one salvage regimen who are ineligible for allogeneic stem cell transplant (alloSCT) or have refractory disease activity precluding alloSCT at this time, or * patients who have relapsed post alloSCT at least 100 days posttransplant, with no evidence of active GVHD, and no longer taking immunosuppressive agents for at least 30 days prior to enrollment. * patients with Ph+ ALL if they are intolerant to tyrosine kinase inhibitor (TKI) therapy, or if they have r/r disease after treatment with at least 2 different TKIs. * ALL patients with combined bone marrow and CNS and/or testicular relapse are eligible only if the extramedullary disease has been successfully clea…